Pharmacodynamics to combat resistance

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue TOPIC T1, 2000, Pages 25-31

  Woodnutt, Gary ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CEFUROXIME; CIPROFLOXACIN; CLAVULANIC ACID; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLONE DERIVATIVE; SITAFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG EFFICACY; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PHARMACODYNAMICS; RAT; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIA;

EID: 0033910923     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.jac.a020890     Document Type: Article

References (23)

1. Craig, W. A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26, 1-12.
2. Drusano, G. L. & Craig, W. A. (1997). Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Journal of Chemotherapy 9, Suppl. 3, 38-44.
3. Craig, W. A. & Ebert, S. C. (1990). Killing and regrowth of bacteria in vitro: a review. Scandinavian Journal of Infectious Diseases 74, Suppl., 63-70.
4. Craig, W. A. (1995). Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broadspectrum cephalosporins. Diagnostic Microbiology and Infectious Disease 22, 89-96.
5. Craig, W. A. (1996). Antimicrobial resistance issues of the future. Diagnostic Microbiology and Infectious Disease 25, 213-7.
6. Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W. et al. (1989). Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. Journal of Infectious Diseases 159, 281-92.
7. Forrest, A., Nix, D. E., Ballow, C. H., GOSS, T. F., Birmingham, M. C. & Schentag, J. J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, 1073-81.
8. Preston, S. L., Drusano, G. L., Berman, A. L., Fowler, C. L., Chow, A. T., Dornseif, B. et al. (1998). Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Journal of the American Medical Association 279, 125-9.
9. Cormican, M. G. & Jones, R. N. (1997). Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrobial Agents and Chemotherapy 41, 204-11.
10. Moore, T., Kershner, K., Donald, B., Rittenhouse, S. & Coleman, K. (1999). Post-antibiotic effect (PAE) of gemifloxacin (SB-265805) and ciprofloxacin against Gram-positive and Gram-negative organisms. In Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 2298, p. 278. American Society for Microbiology, Washington, DC.
11. Credito, K. L., Clark, C. L., Jacobs, M. R. & Appelbaum, P. C. (1999). Post-antibiotic effect (PAE) of gemifloxacin (SB-265805) compared with five other quinolones against pneumococci. In Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 537, p. 21. American Society for Microbiology, Washington, DC.
12. Kim, M.-Y., Paek, K.-S. & Choo, Y. S. (1998). SB-265805 (LB20304a): Post-antibiotic effects on Staphylococcus aureus and Escherichia coli. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract F-088, p. 255. American Society for Microbiology, Washington, DC.
13. Paek, K.-S., Kim, M.-Y. & Choo, Y. S. (1998). SB-265805 (LB20304a): Bactericidal activity against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. In Program and Abstracts of the Thirty-Eighth Interscience Conference of Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract F-091, p. 255. American Society for Microbiology, Washington, DC.
14. Paek, K.-S., Kim, M.-Y. & Choo, Y. S. (1998). SB-265805 (LB20304a): bactericidal activity against respiratory tract pathogens. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract F-094, p. 256. American Society for Microbiology, Washington, DC.
15. Andes, D. & Craig, W. A. (1999). Pharmacodynamics of gemifloxacin (GEM) against quinolone-resistant strains of S. pneumoniae (SP) with known resistance mechanisms. In Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 2032, p. 50. American Society for Microbiology, Washington, DC.
16. Andes, D. & Craig, W. A. (1999). In vivo pharmacodynamic activity of gemifloxacin (GEM) against multiple bacterial pathogens. In Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 27, p. 8. American Society for Microbiology, Washington, DC.
17. Andes, D. & Craig, W. A. (1999). In vivo pharmacodynamic activity of sitafloxacin (SIT) against multiple bacterial pathogens. In Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 28, p. 9. American Society for Microbiology, Washington, DC.
18. Andes, D. & Craig, W. A. (1999). In vivo pharmacodynamic activity of gatifloxacin (GAT) against multiple bacterial pathogens. In Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 191, p. 10. American Society for Microbiology, Washington, DC.
19. Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. H. et al. (1998). Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrobial Agents and Chemotherapy 42, 521-7.
20. Berry, V., Page, R., Satterfield, J., Singley, C., Straub, R. & Woodnutt, G. (1999). Comparative efficacy of gemifloxacin against respiratory tract infection in rats caused by Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 44, Suppl. A, 148.
21. Berry, V., Page, R., Satterfield, J., Straub, R. & Woodnutt, G. (1999). Comparative efficacy of gemifloxacin against experimental RTI in rats caused by Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 44, Suppl. A, 146.
22. Berry, V., Page, R., Satterfield, J., Singley, C., Straub, R. & Woodnutt, G. (1999). Comparative efficacy of gemifloxacin (SB-265805) against experimental respiratory tract infection in rats caused by ciprofloxacin-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae. In Program and Abstracts of the Thirty-Ninth Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 1548, p. 76. American Society for Microbiology, Washington, DC.
23. Berry, V., Page, R., Singley, C., Straub, R. & Woodnutt, G. (1999). Comparative efficacy of gemifloxacin against S. pyogenes and Staphylococcus spp. in skin and soft tissue infections in rats. Journal of Antimicrobial Chemotherapy 44, Suppl. A, 148.